BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38689217)

  • 1. Evaluation of the "Burgenland PREvention trial of colorectal cancer Disease with ImmunologiCal Testing" (B-PREDICT)-a population-based colorectal cancer screening program.
    Brezina S; Leeb G; Baierl A; Gräf E; Hackl M; Hofer P; Lang H; Klein M; Mach K; Schwarzer R; Wlassits W; Püspök A; Gsur A
    BMC Gastroenterol; 2024 Apr; 24(1):149. PubMed ID: 38689217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan.
    Sakata N; Sakata Y; Shimoda R; Sakata H; Iwakiri R; Fujimoto K; Mizuguchi M; Irie H; Shimoda Y; Noshiro H
    Hepatogastroenterology; 2014; 61(133):1224-8. PubMed ID: 25436287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline.
    Helsingen LM; Vandvik PO; Jodal HC; Agoritsas T; Lytvyn L; Anderson JC; Auer R; Murphy SB; Almadi MA; Corley DA; Quinlan C; Fuchs JM; McKinnon A; Qaseem A; Heen AF; Siemieniuk RAC; Kalager M; Usher-Smith JA; Lansdorp-Vogelaar I; Bretthauer M; Guyatt G
    BMJ; 2019 Oct; 367():l5515. PubMed ID: 31578196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
    Almansoori A; Alzaabi M; Alketbi L
    BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark.
    Larsen MB; Njor S; Ingeholm P; Andersen B
    Gastroenterology; 2018 Jul; 155(1):99-106. PubMed ID: 29626451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study.
    Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I
    BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system.
    Singal AG; Gupta S; Tiro JA; Skinner CS; McCallister K; Sanders JM; Bishop WP; Agrawal D; Mayorga CA; Ahn C; Loewen AC; Santini NO; Halm EA
    Cancer; 2016 Feb; 122(3):456-63. PubMed ID: 26535565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial.
    Randel KR; Schult AL; Botteri E; Hoff G; Bretthauer M; Ursin G; Natvig E; Berstad P; Jørgensen A; Sandvei PK; Olsen ME; Frigstad SO; Darre-Næss O; Norvard ER; Bolstad N; Kørner H; Wibe A; Wensaas KA; de Lange T; Holme Ø
    Gastroenterology; 2021 Mar; 160(4):1085-1096.e5. PubMed ID: 33227280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
    Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
    Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
    Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
    Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.